Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Drug Developers Urged to Adopt Humans as Superorganism Approach

By LabMedica International staff writers
Posted on 26 Jul 2012
A recent review article summarized more than 100 studies relating to the concept that humans are actually “superorganisms” composed of many varieties of eukaryotic and prokaryotic cells.

Most drug development activities have been conducted within a framework that links a single drug with its critical receptor target. More...
However, this approach may change due to increasing interest in understanding the properties of traditional Chinese medicines (TCMs) for their potential utilization as a source of new drugs, since emerging evidence indicates that most TCM drugs are actually targeting both the human host and many of its symbiotic microbes.

Chinese medicine traditionally viewed humans as “superorganisms” comprised of only about 10% human cells with the other 90% of the body being composed of bacterial, fungal, and other cells. These symbiotic microorganisms release molecular signals that can determine whether human genes turn on or off and that can influence the immune system's defenses against disease.

To better understand the superorganism concept investigators at Shanghai Jiao Tong University (Shanghai, China) reviewed more than 100 studies related to this topic in a paper that was published in the July 6, 2012, issue of the Journal of Proteome Research. In this review, they explored the challenges of and opportunities for harmonizing Eastern–Western drug discovery paradigms by focusing on emergent functions at the whole body level of humans as superorganisms.

“This superorganism view of the human body provides a complete new systems concept for managing human health at the clinically relevant whole body level,” said the authors. “It is one of the most significant paradigm shifts in modern medicine."

The review described how this revolutionary change is fostering emergence of an approach called "functional metagenomics" for developing new medicines. This could lead to new drug candidate compounds for chronic diseases targeting receptors outside the currently accepted “druggable genome” and shed light on current high interest issues in Western medicine such as drug-drug and drug-diet-gut microbial interactions that will be crucial in the development and delivery of future therapeutic regimes optimized for the individual patient.

Related Links:

Shanghai Jiao Tong University





Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.